Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Search results
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
X-linked inheritance means that the faulty gene is located on the X chromosome, the larger of the two sex chromosomes.
We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments.
In this article, we hear Colin's story and the reasons why he has hope for the future.
A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards a treatment for a particular type of retinitis pigmentosa.
Caryn talks about her experience taking part in the 2021 Virtual London Marathon.
Pancake Day or Shrove Tuesday, which in 2025 falls on Tuesday 4 March, could be a great opportunity to fundraise for Retina UK, whilst having fun and eating lots of yummy pancakes!
Retina UK invites expressions of interest to their first major innovation grant call, which will result in an award of up to £1million over five years as a strategic and targeted investment to result in transformative impact for therapy for inherited retinal dystrophy.
Saturday 13 September 2025, 11.00am - 1.00pm - In-person - Come and join Valerie and the group when we return to the Festival Theatre in Edinburgh to hear from guest speakers Graham Gunning & Fraser Fleming from TripleTapTech.
These frequently asked questions should provide a response for most of the queries you might raise.